Literature DB >> 7704571

Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells.

S Lovestone1, C H Reynolds, D Latimer, D R Davis, B H Anderton, J M Gallo, D Hanger, S Mulot, B Marquardt, S Stabel.   

Abstract

BACKGROUND: Paired helical filaments (PHFs) are a characteristic pathological feature of Alzheimer's disease; their principal component is the microtubule-associated protein tau. The tau in PHFs (PHF-tau) is hyperphosphorylated, but the cellular mechanisms responsible for this hyperphosphorylation have yet to be elucidated. A number of kinases, including mitogen-activated protein (MAP) kinase, glycogen synthase kinase (GSK)-3 alpha, GSK-3 beta and cyclin-dependent kinase-5, phosphorylate recombinant tau in vitro so that it resembles PHF-tau as judged by its reactivity with a panel of antibodies capable of discriminating between normal tau and PHF-tau, and by a reduced electrophoretic mobility that is characteristic of PHF-tau. To determine whether MAP kinase, GSK-3 alpha and GSK-3 beta can also induce Alzheimer's disease-like phosphorylation of tau in mammalian cells, we studied the phosphorylation status of tau in primary neuronal cultures and transfected COS cells following changes in the activities of MAP kinase and GSK-3.
RESULTS: Activating MAP kinase in cultures of primary neurons or transfected COS cells expressing tau isoforms did not increase the level of phosphorylation for any PHF-tau epitope investigated. But elevating GSK-3 activity in the COS cells by co-transfection with GSK-3 alpha or GSK-3 beta decreased the electrophoretic mobility of tau so that it resembled that of PHF-tau, and induced reactivity with eight PHF-tau-selective monoclonal antibodies.
CONCLUSIONS: Our data indicate that GSK-3 alpha and/or GSK-3 beta, but not MAP kinase, are good candidates for generating PHF-type phosphorylation of tau in Alzheimer's disease. The involvement of other kinases in the generation of PHFs cannot, however, be eliminated. Our results suggest that aberrant regulation of GSK-3 may be a pathogenic mechanism in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7704571     DOI: 10.1016/s0960-9822(00)00246-3

Source DB:  PubMed          Journal:  Curr Biol        ISSN: 0960-9822            Impact factor:   10.834


  108 in total

1.  Hyperactivation of mitogen-activated protein kinase increases phospho-tau immunoreactivity within human neuroblastoma: additive and synergistic influence of alteration of additional kinase activities.

Authors:  F J Ekinci; T B Shea
Journal:  Cell Mol Neurobiol       Date:  1999-04       Impact factor: 5.046

2.  NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy.

Authors:  Raquel Gómez-Sintes; José J Lucas
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

Review 3.  Understanding protein non-folding.

Authors:  Vladimir N Uversky; A Keith Dunker
Journal:  Biochim Biophys Acta       Date:  2010-02-01

4.  A useful approach to identify novel small-molecule inhibitors of Wnt-dependent transcription.

Authors:  Kenneth Ewan; Bozena Pajak; Mark Stubbs; Helen Todd; Olivier Barbeau; Camilo Quevedo; Hannah Botfield; Rodrigo Young; Ruth Ruddle; Lee Samuel; Alysia Battersby; Florence Raynaud; Nicholas Allen; Stephen Wilson; Branko Latinkic; Paul Workman; Edward McDonald; Julian Blagg; Wynne Aherne; Trevor Dale
Journal:  Cancer Res       Date:  2010-07-07       Impact factor: 12.701

5.  Structural genomics analysis of alternative splicing and application to isoform structure modeling.

Authors:  Peng Wang; Bo Yan; Jun-Tao Guo; Chindo Hicks; Ying Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-14       Impact factor: 11.205

Review 6.  Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics.

Authors:  Richard S Jope; Christopher J Yuskaitis; Eléonore Beurel
Journal:  Neurochem Res       Date:  2006-08-30       Impact factor: 3.996

7.  Dishevelled regulates the metabolism of amyloid precursor protein via protein kinase C/mitogen-activated protein kinase and c-Jun terminal kinase.

Authors:  A Mudher; S Chapman; J Richardson; A Asuni; G Gibb; C Pollard; R Killick; T Iqbal; L Raymond; I Varndell; P Sheppard; A Makoff; E Gower; P E Soden; P Lewis; M Murphy; T E Golde; H T Rupniak; B H Anderton; S Lovestone
Journal:  J Neurosci       Date:  2001-07-15       Impact factor: 6.167

8.  Pazopanib Reduces Phosphorylated Tau Levels and Alters Astrocytes in a Mouse Model of Tauopathy.

Authors:  Monica Javidnia; Michaeline L Hebron; Yue Xin; Nikolas G Kinney; Charbel E-H Moussa
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

9.  The role of tau phosphorylation in transfected COS-1 cells.

Authors:  M Medina; E Montejo de Garcini; J Avila
Journal:  Mol Cell Biochem       Date:  1995-07-05       Impact factor: 3.396

10.  Parkin attenuates wild-type tau modification in the presence of beta-amyloid and alpha-synuclein.

Authors:  Charbel E-H Moussa
Journal:  J Mol Neurosci       Date:  2008-06-17       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.